2025-10-14 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX) based on the information you provided.

## RXRX (Recursion Pharmaceuticals Inc) Analysis

**Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging AI to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -11.72%
*   **VOO Cumulative Return:** 38.67%
*   **Absolute Divergence:** -55.39%
*   **Relative Divergence:** 6.1 (Ranges from Max: 84.1, Min: -64.3)

**Analysis:** RXRX has significantly underperformed the S&P 500 over the period covered by the cumulative returns. The relative divergence of 6.1 suggests that RXRX is currently near the lower end of its historical divergence range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2021-2023  | 22.0%  | 81.0% | 26.0%  | -0.2  | 4.3    |
| 2022-2024  | 11.0%  | 81.0% | -10.0% | 0.1   | 3.0    |
| 2023-2025  | 31.0%  | 80.0% | -30.0% | 0.1   | 2.4    |

**Analysis:**

*   **CAGR:** RXRX's Compounded Annual Growth Rate varies significantly across the different periods, showcasing high volatility.
*   **MDD:** The Maximum Drawdown is consistently high (around 80%), indicating substantial risk and potential for significant losses.
*   **Alpha:** Alpha is inconsistent, indicating that RXRX's performance relative to the market (S&P 500) is not stable. It shows overperformance during 2021-2023 but underperformance in later periods.
*   **Beta:** The Beta is low (close to 0), suggesting that RXRX's price movements are not strongly correlated with the market.
*   **Cap:** The Market Capitalization has decreased over the periods, indicating potential investor concern or market changes.

### 2. Recent Stock Price Movement

*   **Current Price:** 5.53
*   **Previous Close:** 5.32
*   **Change:** 3.95%
*   **5-Day Moving Average:** 5.508
*   **20-Day Moving Average:** 5.1238
*   **60-Day Moving Average:** 5.2597

**Analysis:** The stock price has recently increased (3.95% change). The current price is above the 5-day, 20-day, and 60-day moving averages, which could suggest short-term upward momentum. The price surge relative to the previous close indicates a potential short-term positive catalyst.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 57.89
*   **PPO:** 1.13
*   **Hybrid Signal:** Buy 100% (195 shares), Monthly invest 1.8% of total investment ($1,000.00), Cash Ratio: 0% on 2025-10-01
*   **Delta_Previous_Relative_Divergence (20-day):** -2.0 (Short-term Decrease)
*   **Expected Return:** -68.1%

**Analysis:**

*   The MRI of 0.8 suggests a medium level of investment risk.
*   The RSI of 57.89 is near the neutral zone, indicating neither overbought nor oversold conditions.
*   The PPO of 1.13 is slightly positive, suggesting a slight upward trend.
*   The Hybrid Signal strongly recommends buying, indicating confidence in the stock despite other risks.
*   The negative change in relative divergence suggests weakening performance compared to the S&P 500 in the short term.
*   The deeply negative expected return (-68.1%) indicates significant expected underperformance compared to the S&P 500 over the long term (2+ years), even with dollar-cost averaging.

### 4. Recent News & Significant Events

*   **Positive Headlines:** Recent news highlights renewed interest due to AI initiatives, with some reports indicating a bullish outlook. The stock has seen significant gains ahead of an AI conference.
*   **Mixed Headlines:** Other headlines point to RXRX dipping more than the broader market and assessing valuation in light of a key CEO presentation.

**Analysis:** The news sentiment is mixed, with both positive catalysts (AI focus, conference anticipation) and concerns (underperformance, valuation questions) present.

#### 4.2 Analyst Opinions

*   **Consensus:** Hold
*   **Mean Rating:** 2.62 (Hold)
*   **Number of Opinions:** 6
*   **Target Price (Avg/High/Low):** 6.47 / 10.00 / 3.00
*   **Recent Rating Changes:** No specific rating changes provided.

**Analysis:** Analyst consensus is a "Hold" with a target price range indicating moderate upside potential based on the average. The lack of recent rating changes suggests that analysts are currently maintaining their existing outlook on the stock.

### 5. Recent Earnings Analysis

| 날짜         | EPS   | 매출        |
|--------------|-------|-------------|
| 2025-08-05   | -0.41 | 0.02 B$     |
| 2025-05-05   | -0.5  | 0.01 B$     |
| 2024-11-06   | -0.34 | 0.03 B$     |
| 2024-08-08   | -0.4  | 0.01 B$     |
| 2025-08-05   | -0.4  | 0.01 B$     |

**Analysis:** Recursion Pharmaceuticals has consistently reported negative EPS figures. Revenue has fluctuated but remains relatively low.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | \$0.02B   | -5.54%        |
| 2025-03-31 | \$0.01B   | -47.31%       |
| 2024-12-31 | \$0.00B   | -183.62%      |
| 2024-09-30 | \$0.03B   | 53.69%        |
| 2024-06-30 | \$0.01B   | 36.14%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-06-30 | \$0.92B   | -18.70%   |
| 2025-03-31 | \$0.93B   | -21.68%   |
| 2024-12-31 | \$1.03B   | -17.29%   |
| 2024-09-30 | \$0.52B   | -18.27%   |
| 2024-06-30 | \$0.58B   | -16.69%   |

**Analysis:**

*   **Revenue:** Revenue generation is inconsistent and generally low.
*   **Profit Margin:** Profit margins are highly variable, with some quarters showing positive margins, but many showing significant losses.
*   **Equity:** Equity has fluctuated but remains relatively high.
*   **ROE:** ROE is consistently negative, indicating that the company is not generating profits from its equity.

### 7. Overall Analysis and Summary

Recursion Pharmaceuticals (RXRX) presents a mixed picture:

*   **Underperformance:** The stock has significantly underperformed the S&P 500, with a large negative cumulative return divergence.
*   **Financials:** Revenue generation is inconsistent, and the company is not yet profitable, resulting in negative EPS and ROE.
*   **Volatility:** The stock is highly volatile, as reflected in the high Maximum Drawdown (MDD).
*   **AI Focus:** The company's focus on AI in drug discovery is a potential positive catalyst, driving some recent stock gains and analyst optimism.
*   **Mixed Signals:** The news sentiment is mixed, and analyst consensus is a "Hold."
*   **Risk Tolerance:** The MRI suggests a medium level of investment risk, but the negative expected return suggests caution.
*   **Recent Surge:** The recent price surge indicates short-term positive momentum, potentially driven by the AI conference and related news.

**Conclusion:** RXRX is a high-risk, high-reward investment. While the AI-driven approach holds promise and has generated recent positive attention, the company's financial performance, negative expected return, and historical underperformance compared to the S&P 500 warrant caution. Investors should carefully consider their risk tolerance and conduct further due diligence before investing.
